Intravitreal Aflibercept versus Ranibizumab for Diabetic Macular Edema in a Taiwanese Health Service Setting.

To compare the visual and anatomical outcomes between intravitreal aflibercept and ranibizumab for diabetic macular edema A total of 194 eyes from 194 patients (aflibercept n = 95, ranibizumab n = 99) were retrospectively enrolled in the study. All eyes fulfilled the key criteria including a baseline best-corrected visual acuity (BCVA) between 20 and 70 ETDRS letters, a central subfield thickness (CST) 300 µm or more. Primary outcomes were BCVA and CST at 1, 3, 6, and 12 months. Maintenance of vision was defined as visual loss of less than 5 letters over 6 to 12 months. Predictors for final visual acuity and visual maintenance were analyzed using multivariate regression models. Both agents achieved comparable visual and anatomical outcomes at any time point over the course of follow-up (all > .05). At 12 months, aflibercept group had higher proportions of visual gains 5, 10 and 15 letters or more ( = .014, = .011, and = .034, respectively). The mean number of injections was 5.0 ± 1.9 in ranibizumab group and 4.5 ± 1.9 in aflibercept group ( = .09). Ranibizumab predicted poor maintenance of vision ( = .009), but not the final visual acuity (univariate = .1). Ranibizumab was more likely to have recurrence of subretinal fluid than aflibercept in 12 months after resolution of subretinal fluid at baseline ( = .016). Both aflibercept and ranibizumab had similar rates of loss to follow-up ( = .47) and occurrence of vitreous hemorrhage ( = .21). While both agents improved vision with resolution of edema, aflibercept maintained vision more effectively with less recurrence of subretinal fluid at 12 months in real-world settings.